Molecular diagnostics detect and measure
theexistence of genetic material or proteinsassociated with a specific health
conditionor disease to uncover theunderlying mechanisms of disease andenabling
clinicians to tailor care at an individual level. These tests are useful in
various medical special areas including infectious disease, human leucocyte
antigen typing, oncology, coagulation, and pharmacogenomics.
According to study, “Worldwide
Molecular Diagnostics Market Trends and Drivers, Restraints, and Opportunities
2017-2023” some of the major companies that are currently working in
the worldwide molecular diagnostics market areHologic, Inc, F. Hoffmann-la
Roche, Danaher Corporation, Siemens Healthineers Inc., Qiagen N.V., Abbott
Laboratories, Becton Dickenson and Company, Quest Diagnostics Inc., Abbott
Molecular, Tecan Group Ltd., Hoffmann-La Roche Ltd., Illumina, Inc., Diasorin,
Grifols International S.A, Advanced Cell Diagnostics, The ELI TechGroup, Roche
Diagnostics, Siemens Healthineers Inc., Hologic Corporation, Agilent
Technologies/Dako, Amoy Diagnostics, Meridian Bioscience, Biocartis, Genmark
Diagnostics, Beijing Genomics Institute (BGI), Myriad Genetics, Bio-ad
Laboratories Inc, Exosome Diagnostics, Nanostring Technologies, Applied
Spectral Imaging, Laboratory Corporation of America, Orchid Biosciences and
Dianon Cellmark Forensics, American Association of Blood Banks, Ariosa
Diagnostics, Chronix Biomedical, PerkinElmer, Inc. (PE), Signature Diagnostics,
Central Drugs Standard Control Organization, Great Basin Scientific, Genomic
Health Inc., Cepheid Inc., Thermo Fisher Scientific, bioMerieux S.A.
Based on the technology, the worldwide
molecular diagnostic market is segmented into chips & microarrays,
Isothermal Nucleic Acid Amplification Technology (INAAT), Transcription
Mediated Amplification (TMA), Fluorescence In-Situ hybridization, molecular
imaging, cytogenetics, gene expression-based studies, Polymerase Chain Reaction
(PCR) based methods, mass spectroscopy and DNA sequencing. Hybridization is
further sub-segmented into In-Situ Hybridization (ISH) and Fluorescence In-Situ
Hybridization (FISH). Molecular imaging is sub-segmented into FDG-PET and
optical imaging. PCR based methods include Cold-PCR, directlinear analysis,
real-time PCR, digital-PCR, reverse transcriptase PCR and quantitative
fluorescent PCR. DNA sequencing includes Next Generation Sequencing (NGS) and
Capillary Electrophoresis (CE).
Some of the major advantages of the molecular
diagnostic techniques includesensitive & specific, ease of testing, and
rapid turnaround time (TAT) and large volume testing. Based on the application,
the market is segmented into oncology, human leukocyte antigen
typing,infectious disease, pharmacogenomics, blood screening, genetic disease
screening and microbiology. Infectious disease includes human immunodeficiency
virus (HIV), meningitis, flu, tuberculosis, Chlamydia Trachomatis or Neisseria
gonorrhoeae CT/NG, Human papilloma virus (HPV), TB, H.Pylori, dengue,
influenza, TORCH and hepatitis.
The market of molecular diagnostics is mainly
driven by large outbreaks of bacterial & viral epidemics followed by
evolving technologies, pharmacogenomics, increasing awareness & acceptance
of adapted medicine & companion diagnostics, higher expenditure in life
science, increasing patient with bone disorders, increasing government support,
concentration of major companies, high prevalence of infectious diseases &
different types of cancers, and increasing demand for the point- of-care
diagnostics. However, market is also impactedby the restraints such ashigh
complexity testing centers, lack of proper reimbursement policies, complex
regulatory frameworks, economic turndown and limited budget. Additionally, some
new prospects include growth opportunities in emerging markets and advances in
genomics & proteomics.
America leads the global market for molecular
diagnostics owing to growing demand for the advanced techniques & molecular
diagnostics. It is estimated that the molecular diagnostics market to reach at
US $11.5 billion by 2023 from US$7.1 billion in 2017, at a CAGR of 8.4%.
For more information, click on the
link below:
Contact Us:
Ken
Research
Ankur
Gupta, Head Marketing & Communications
+91
9015378249